EP0057
Phase 2Small molecule
EP0057 is one of 103 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.
3
Indications
3
Total Trials
0
Active Trials
102
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Tecentriq
RochePhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Novantrone
PfizerPhase 3
Piqray
NovartisPhase 3
Veliparib
AbbViePhase 3
Arimidex
IIstituto Clinico Humanitas
Phase 3
Investigator's Choice of Chemotherapy
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3
VB-111
VVascular Biogenics Ltd. operating as VBL Therapeutics
Phase 3
GSK5733584
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EP0057. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEllipses Pharma